Delving into the Latest Updates on Chongqing Kerui Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Infectious Diseases

Urogenital Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

PBPs x β-lactamase	1

主要研究目的：本研究以重庆科瑞制药（集团）有限公司生产的奥美沙坦酯片（规格：20mg）为受试制剂，第一三共制药（上海）有限公司的奥美沙坦酯片（商品名：傲坦®；规格：20mg）为参比制剂，评价受试制剂和参比制剂在空腹/餐后条件下给药时的生物等效性。次要研究目的：观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Main research purpose: This study uses Olmesartan Medoxomil Tablets (specification: 20 mg) produced by Chongqing Kerui Pharmaceutical (Group) Co., Ltd. as the test preparation and Olmesartan Medoxomil Tablets (trade name: Aotan®; specification: 20 mg) produced by Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation when administered under fasting/postprandial conditions. Secondary research purpose: Observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date11 May 2021

Sponsor / Collaborator

Chongqing Kerui Pharmaceutical Co. Ltd.

CTR20210735 / CompletedNot Applicable

普瑞巴林胶囊在中国健康受试者中的单次给药、随机、开放、两周期、两序列、双交叉、空腹和餐后状态下的生物等效性研究

[Translation] A single-dose, randomized, open-label, two-period, two-sequence, double-crossover, fasting and fed bioequivalence study of pregabalin capsules in Chinese healthy subjects

主要目的：本研究以重庆科瑞制药（集团）有限公司生产的普瑞巴林胶囊为受试制剂，以Pfizer Manufacturing Deutschland GmbH,Betriebsstatte Freiburg生产、辉瑞制药有限公司进口分包装的普瑞巴林胶囊（Lyrica）为参比制剂，对比两制剂在空腹和餐后条件下，在健康人体内的吸收速度和吸收程度，评价两制剂间的生物等效性。次要目的：观察受试制剂普瑞巴林胶囊和参比制剂普瑞巴林胶囊（Lyrica）在健康受试者中的安全性。

[Translation]

Main purpose: This study used pregabalin capsules produced by Chongqing Kerui Pharmaceutical (Group) Co., Ltd. as the test preparation, and pregabalin capsules (Lyrica) produced by Pfizer Manufacturing Deutschland GmbH, Betriebsstatte Freiburg and imported and packaged by Pfizer Pharmaceutical Co., Ltd. as the reference preparation. The absorption rate and degree of the two preparations in healthy people under fasting and postprandial conditions were compared to evaluate the bioequivalence between the two preparations. Secondary purpose: To observe the safety of the test preparation pregabalin capsules and the reference preparation pregabalin capsules (Lyrica) in healthy subjects.

Start Date06 May 2021

Sponsor / Collaborator

Chongqing Kerui Pharmaceutical Co. Ltd.

CTR20210341 / CompletedNot Applicable

本试验采用单中心、随机、开放、单剂量、两制剂、四周期、两序列完全重复交叉设计，分为空腹给药和餐后给药人体生物等效性研究两部分。

[Translation] This study adopted a single-center, randomized, open, single-dose, two-drug, four-period, two-sequence completely repeated crossover design, which was divided into two parts: fasting administration and postprandial administration human bioequivalence study.

本试验旨在研究单次空腹和餐后口服重庆科瑞制药（集团）有限公司研制、生产的盐酸普拉格雷片（5 mg）的药代动力学特征；以第一三共株式会社生产的盐酸普拉格雷片（Efient®，5 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。

[Translation]

The aim of this study was to investigate the pharmacokinetic characteristics of prasugrel hydrochloride tablets (5 mg) developed and produced by Chongqing Kerui Pharmaceutical (Group) Co., Ltd. after single fasting and postprandial oral administration; using prasugrel hydrochloride tablets (Efient®, 5 mg) produced by Daiichi Sankyo Co., Ltd. as the reference preparation, the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared, and the bioequivalence of the two preparations in humans was evaluated.

Start Date19 Apr 2021

Sponsor / Collaborator

Chongqing Kerui Pharmaceutical Co. Ltd.

100 Clinical Results associated with Chongqing Kerui Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Chongqing Kerui Pharmaceutical Co. Ltd.

Login to view more data

19

Literatures (Medical) associated with Chongqing Kerui Pharmaceutical Co. Ltd.

25 Jun 2024·Zeitschrift für Kristallographie - New Crystal Structures

The crystal structure of (E)-1-(((2-amino-4,5-dimethylphenyl)iminio)methyl)naphthalen-2-olate, C₁₉H₁₈N₂O

Author: Xiong, Hai-Lin ; Zhang, Jian-Guo ; Zou, Hao

AbstractC19H18N2O, orthorhombic, Pna21 (no. 33), a = 21.838(2) Å, b = 13.9663(11) Å, c = 4.9806(4) Å, V = 1519.1(2) Å3, Z = 4, Rgt(F) = 0.0702, wRref(F2) = 0.1948, T = 293 K.

15 Dec 2023·Zeitschrift für Kristallographie - New Crystal Structures

Crystal structure of dichlorido-bis[2-(2,4-difluorophenyl)pyridine-κ ¹N]platinum(II), C₂₂H₁₄Cl₂F₄N₂Pt

Author: Tan, Wei ; Cheng, Chen-En-Ze ; Zou, Hao ; Zhang, Jian-Guo

AbstractC22H14Cl2F4N2Pt, monoclinic, P21/n (no. 14), a = 16.858(9) Å, b = 14.876(8) Å, c = 17.125(9) Å, β = 98.552(6)°, V = 4247(4) Å3, Z = 8, Rgt(F) = 0.0337, wRref(F2) = 0.0778, T = 296 K.

26 Oct 2023·Zeitschrift für Kristallographie - New Crystal Structures

Crystal structure of chlorido-(5-nitro-2-phenylpyridine-κ² N,C)-[(methylsulfinyl)methane-κ¹ S]platinum(II), C₁₃H₁₃ClN₂O₃PtS

Author: Zou, Hao ; Tan, Wei ; Zhang, Jian-Guo

AbstractC13H13ClN2O3PtS, monoclinic, C2/c (no. 15), a = 7.9405(8) Å, b = 18.0744(18) Å, c = 21.513(2) Å, β = 98.781(1)∘, Z = 8, V = 3051.3(5) Å3, Rgt(F) = 0.0535, wRref(F2) = 0.0233, T = 296 K.

100 Deals associated with Chongqing Kerui Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Chongqing Kerui Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data